# SPRO catalysts: Spero Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/spro/catalysts

> Spero Therapeutics, Inc. (SPRO) has 1 upcoming catalyst. The next is the SP001 trial start, Q2 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SPRO?

Spero Therapeutics, Inc. (SPRO) has 1 upcoming catalyst. The next is the SP001 trial start, Q2 2027. Press release filed with the SEC (EX-99): "Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027." [Calendar and source filings](https://sec-api.dev/companies/spro/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-458637, https://www.sec.gov/Archives/edgar/data/1701108/000119312526458637/spro-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-12. Cite: https://sec-api.dev/companies/spro/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Spero Therapeutics, Inc. |
| Ticker | SPRO (Nasdaq) |
| SEC CIK | 1701108 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/spro |

## Cash runway

Cash $107.9M as of 2026-09-30; quarterly burn $42.6M; about 7.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-458593).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2022 | [Tebipenem complete response letter (CRL)](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | completed, complete response letter | "In June 2022, we received a Complete Response Letter ("CRL") from the FDA regarding our NDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm)) |
| Dec 2022 | [Tebipenem NDA/BLA acceptance](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | completed | "We included data from our completed ADAPT-PO Phase 3 clinical trial of tebipenem HBr, together with requisite safety data, chemistry, manufacturing and controls ("CMC") information, clinical pharmacology and nonclinical studies, in our New Drug Application ("NDA") submission to the FDA, which was accepted by the FDA in late December 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1701108/000095017025046125/spro-20241231.htm)) |
| October 29, 2024 | [SPR720 interim data readout](https://sec-api.dev/pdufa/spr720) | SPRO | NTM-PD not meeting its primary endpoint | completed, met | "On October 29, 2024, we announced that we suspended development activities for our SPR720 oral program based on an interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of NTM-PD not meeting its primary endpoint." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm)) |
| November 14, 2024 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 14, 2024  Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312524258540/d915138dex991.htm)) |
| March 27, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525065633/d906623dex991.htm)) |
| Q2 2025 | [Tebipenem interim data readout](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | scheduled | "This pre-specified interim analysis is expected in Q2 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635dex991.htm)) |
| May 13, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525118882/d918635dex991.htm)) |
| 2H 2025 | [Carbapenem topline data readout](https://sec-api.dev/pdufa/carbapenem) | SPRO |  | scheduled | "2H 2025 milestones  Strong global intellectual  Phase 3 data readout and property regulatory submission (US) expected in 2H 20251  GSK commercial partnership with strong economics" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525004063/d820907dex991.htm)) |
| July 15, 2025 | [Spero Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000095017025107388/spro-20250630.htm)) |
| August 12, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., Aug 12, 2025  Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/d97572dex991.htm)) |
| November 13, 2025 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 13, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the third quarter ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/d44321dex991.htm)) |
| December 19, 2025 | [Tebipenem NDA/BLA submission](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed | "On December 19, 2025, Spero Therapeutics, Inc. (the "Company") announced that its tebipenem HBr development partner, GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK"), filed a New Drug Application ("NDA") resubmission to the U.S. Food and Drug Administration for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312525325821/d212013d8k.htm)) |
| March 26, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475dex991.htm)) |
| May 13, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., May 13, 2026 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm)) |
| Jun 2026 | [SP001 FDA approval](https://sec-api.dev/pdufa/sp001) | SPRO |  | completed, approved | "In June 2026, the U.S. Food and Drug Administration ("FDA") approved GSK's NDA resubmission for Utebzi, and we have since shifted our focus and resources to advancing the development of SP001." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm)) |
| June 17, 2026 | [Tebipenem FDA approval](https://sec-api.dev/pdufa/tebipenem) | SPRO | complicated urinary tract infections | completed, approved | "On June 17, 2026, the Company and GSK announced that the FDA approved GSK's NDA resubmission for Utebzi (tebipenem pivoxil)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm)) |
| June 18, 2026 | [Tebipenem PDUFA date](https://sec-api.dev/pdufa/tebipenem) | SPRO |  | completed, approved | "New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526221567/d147628dex991.htm)) |
| June 18, 2026 | [Carbapenem PDUFA date](https://sec-api.dev/pdufa/carbapenem) | SPRO |  | scheduled | "FDA approval was received in advance of FDA-assigned Prescription Drug User Fee Act ("PDUFA") date of June 18, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1701108/000119312526277506/d51395d8k.htm)) |
| August 12, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., Aug 12, 2026 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249dex991.htm)) |
| August 12, 2026 | [SP001 FDA approval](https://sec-api.dev/pdufa/sp001) | SPRO |  | completed, approved | "We entered the quarter as a company preparing for an important regulatory milestone and have since then announced the FDA approval of Utebzi; a new Phase 2-ready immunology program with SP001; and financing that positions us to continue executing on our mission to deliver transformative therapies to patients," said Esther Rajavelu, President and Chief Executive Officer of Spero." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249dex991.htm)) |
| November 12, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "CAMBRIDGE, Mass., November 12, 2026 - Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for immune-mediated diseases, today announced financial results for the third quarter ended September 30, 2026, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458637/spro-ex99_1.htm)) |
| Q2 2027 | [SP001 trial start](https://sec-api.dev/pdufa/sp001) | SPRO |  | scheduled | "Spero plans to initiate a Phase 2 study for SP001 in IgG4-RD in Q2 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526458637/spro-ex99_1.htm)) |

## Drugs

- [SP001](https://sec-api.dev/pdufa/sp001): 
- [SPR720](https://sec-api.dev/pdufa/spr720): ntm-pd not meeting its primary endpoint
- [Tebipenem](https://sec-api.dev/pdufa/tebipenem): complicated urinary tract infections

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/spro/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SPRO catalysts: Spero Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/spro/catalysts

```bibtex
@misc{secapidev_companies_spro_catalysts_20261116,
  title        = {SPRO catalysts: Spero Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/spro/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_spro_catalysts_20261116","title":"SPRO catalysts: Spero Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/spro/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
